A Randomized, Parallel-group, Placebo-controlled Subject and Investigator Blinded Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of QCC374 in the Treatment of Pulmonary Arterial Hypertension
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs QCC 374 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 25 Feb 2018 Planned End Date changed from 25 Apr 2019 to 27 Dec 2018.
- 25 Feb 2018 Planned primary completion date changed from 26 Mar 2019 to 27 Dec 2018.
- 25 Feb 2018 Status changed from not yet recruiting to recruiting.